NCT04262479 - Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions

Latent Autoimmune Diabetes in Adults

Interventions

DRUG

recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel

3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden

DRUG

Vitamin D

1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden

Trial Locations (2)

Department of Endocrinology, St Olavs Hospital, Trondheim

Akademiskt Specialistcentrum, Centrum for Diabetes, and Karolinska Institute, Stockholm